Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
The novel centrally acting analgesic tapentadol [(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride] combines two mechanisms of action, μ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition (NRI), in a single molecule. Pharmacological antagonism studies have demonstrated that both mechanisms of action contribute to the analgesic effects of tapentadol. This study was designed to investigate the nature of the interaction of the two mechanisms. Dose-response curves were generated in rats for tapentadol alone or in combination with the opioid antagonist naloxone or the α(2)-adrenoceptor antagonist yohimbine. Two different pain models were used: 1) low-intensity tail-flick and 2) spinal nerve ligation. In each model, we obtained dose-effect relations to reveal the effect of tapentadol based on MOR agonism, NRI, and unblocked tapentadol. Receptor fractional occupation was determined from tapentadol's brain concentration and its dissociation constant for each binding site. Tapentadol produced dose-dependent analgesic effects in both pain models, and its dose-effect curves were shifted to the right by both antagonists, thereby providing data to distinguish between MOR agonism and NRI. Both isobolographic analysis of occupation-effect data and a theoretically equivalent methodology determining interactions from the effect scale demonstrated very pronounced synergistic interaction between the two mechanisms of action of tapentadol. This may explain why tapentadol is only 2- to 3-fold less potent than morphine across a variety of preclinical pain models despite its 50-fold lower affinity for the MOR. This is probably the first demonstration of a synergistic interaction between the occupied receptors for a single compound with two mechanisms of action.
Global Preclinical Research and Development, Department of Pharmacology, Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Germany. wolfgang.schroeder@grunenthal.com
W
W
Schröder
T M
TM
Tzschentke
R
R
Terlinden
J
J
De Vry
U
U
Jahnel
T
T
Christoph
R J
RJ
Tallarida
D000698:Analgesia / Q000379:methods*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D008297:Male; D010147:Pain Measurement / Q000187:drug effects* / Q000379:methods; D010636:Phenols / Q000494:pharmacology*; D011485:Protein Binding / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000378:metabolism; D000077432:Tapentadol
D010636:Phenols; D017450:Receptors, Opioid, mu; D000077432:Tapentadol
J Pharmacol Exp Ther. 2006 Oct;319(1):1-7
16670349
Prog Neurobiol. 2002 Apr;66(6):355-474
12034378
J Pain Symptom Manage. 1996 Apr;11(4):203-17
8869456
Eur J Pain. 2010 Sep;14(8):814-21
20541444
Pharmacol Ther. 2010 Aug;127(2):165-74
20546783
Pain. 1990 Nov;43(2):155-162
2087328
Expert Opin Pharmacother. 2009 Nov;10(16):2687-96
19795998
J Pharmacol Exp Ther. 1990 Dec;255(3):1107-16
2262895
J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
11504778
Arthritis Res Ther. 2005;7(5):R1046-51
16207320
Arzneimittelforschung. 1953 Jun;3(6):285-90
13081480
Pharmacol Ther. 2007 Jan;113(1):197-209
17079019
J Pharmacol Exp Ther. 1987 Jul;242(1):90-5
3612540
Arch Int Pharmacodyn Ther. 1982 Oct;259(2):222-9
7181579
Pain. 1986 Oct;27(1):45-49
3785963
J Pharmacol Exp Ther. 2004 Sep;310(3):981-6
15175417
J Pharmacol Exp Ther. 2007 Oct;323(1):265-76
17656655
Prog Neurobiol. 1999 Jan;57(1):1-164
9987804
Pain. 1987 Mar;28(3):343-355
3494977
Anesth Analg. 1999 Jan;88(1):141-5
9895081
Drug Metab Dispos. 2009 Jul;37(7):1548-56
19389861
Clin Ther. 2009 Feb;31(2):260-71
19302899
Drugs Today (Barc). 2009 Jul;45(7):483-96
19834626
Ann Med. 2000 Jul;32(5):305-16
10949061
Pain. 1983 Jun;16(2):109-110
6877845
Can J Anaesth. 1995 Apr;42(4):292-7
7788826
Anesthesiology. 1990 Dec;73(6):1067-73
2248385
J Pharmacol Exp Ther. 1999 Mar;288(3):1107-16
10027848
Pain. 2004 Dec;112(3):372-380
15561393
J Pharmacol Exp Ther. 2003 Nov;307(2):699-704
12966152
Curr Med Res Opin. 2009 May;25(5):1095-104
19301989
Neurosci Lett. 2010 Feb 12;470(2):91-4
20026182
Pharmacol Rev. 1957 Jun;9(2):237-42
13465303
J Pharmacol Exp Ther. 2008 Jun;325(3):954-60
18339971